Literature DB >> 29125515

Endoscopic Third Ventriculostomy to address hydrocephalus in Africa: A call for education and community-based rehabilitation.

Andres Jimenez-Gomez1, Heidi Castillo2, Caryssa Burckart3, Jonathan Castillo2.   

Abstract

PURPOSE: Endoscopic Third Ventriculostomy (ETV) and Choroid Plexus Cautery (CPC) are low-cost, safe, and promising interventions for spina bifida-associated hydrocephalus (SBHCP). The purpose of this review was to explore and describe these efforts in Africa in order to upscale surgical training and rehabilitation services.
METHODS: A PubMed search for articles on ETV and CPC as management of SBHCP in Africa was performed. Two authors appraised the results for key themes in content: indications, technique, outcomes, complications, education, and rehabilitation.
RESULTS: Twenty of 47 articles identified were included for appraisal. Twelve described indications, ten and seven outlined technique and complications, respectively, and four described predictors of operative success. Fourteen studies describe outcomes, including operative and neurodevelopmental outcomes. Only two outlined educational efforts. Half of the literature stems from a single site in Uganda; in total, only six countries were represented. No articles described significant post-operative rehabilitation services or related training.
CONCLUSION: The experience of ETV and CPC in Africa is promising, however, efforts to train and empower local staff in surgical technique and methods to upscale post-operative community-based rehabilitation services remain as a key to long-term success.

Entities:  

Keywords:  Africa; Myelomeningocele; global health; hydrocephalus; neurosurgery; rehabilitation

Mesh:

Year:  2017        PMID: 29125515     DOI: 10.3233/PRM-170454

Source DB:  PubMed          Journal:  J Pediatr Rehabil Med        ISSN: 1874-5393


  1 in total

Review 1.  Review on myelomeningocele management and its current status in Saudi Arabia.

Authors:  Ibrahim M Alnaami; Eman G Alayad
Journal:  Neurosciences (Riyadh)       Date:  2019-01       Impact factor: 0.735

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.